Travere Therapeutics, Inc. (TVTX)
Largest Insider Buys in Sector
TVTX Stock Price History Chart
TVTX Stock Performance
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola …
Insider Activity of Travere Therapeutics, Inc.
Over the last 12 months, insiders at Travere Therapeutics, Inc. have bought $0 and sold $2.33M worth of Travere Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Travere Therapeutics, Inc. have bought $0 and sold $3.22M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $178,500 was made by ASELAGE STEVE (Chief Executive Officer) on 2017‑06‑14.
List of Insider Buy and Sell Transactions, Travere Therapeutics, Inc.
| 2024-11-25 | Sale | SVP, CHIEF ACCOUNTING OFFICER | 12,090 0.0139% | $18.30 | $221,258 | +3.19% | ||
| 2024-10-04 | Sale | director | 40,000 0.0512% | $14.73 | $589,101 | +18.84% | ||
| 2024-09-30 | Sale | director | 40,000 0.0489% | $14.06 | $562,324 | +28.02% | ||
| 2024-09-10 | Sale | CHIEF MEDICAL OFFICER | 684 0.0009% | $12.98 | $8,878 | +37.77% | ||
| 2024-09-09 | Sale | CHIEF EXECUTIVE OFFICER | 21,125 0.0247% | $11.52 | $243,360 | +37.44% | ||
| 2024-09-09 | Sale | CHIEF COMMERCIAL OFFICER | 2,191 0.0026% | $11.52 | $25,240 | +37.44% | ||
| 2024-09-09 | Sale | SENIOR VICE PRESIDENT, R&D | 4,387 0.0051% | $11.52 | $50,538 | +37.44% | ||
| 2024-09-09 | Sale | SVP, GC & CORPORATE SECRETARY | 4,387 0.0051% | $11.52 | $50,538 | +37.44% | ||
| 2024-09-09 | Sale | CHIEF FINANCIAL OFFICER | 2,490 0.0029% | $11.52 | $28,685 | +37.44% | ||
| 2024-09-09 | Sale | CHIEF MEDICAL OFFICER | 2,191 0.0026% | $11.52 | $25,240 | +37.44% | ||
| 2024-09-04 | Sale | CHIEF FINANCIAL OFFICER | 514 0.0006% | $9.51 | $4,888 | +75.02% | ||
| 2024-04-11 | Sale | CHIEF FINANCIAL OFFICER | 54 <0.0001% | $6.74 | $364 | +43.28% | ||
| 2024-02-01 | Sale | CHIEF EXECUTIVE OFFICER | 19,122 0.0247% | $8.70 | $166,435 | -1.28% | ||
| 2024-02-01 | Sale | CHIEF COMMERCIAL OFFICER | 4,195 0.0053% | $8.53 | $35,789 | -1.28% | ||
| 2024-02-01 | Sale | SENIOR VICE PRESIDENT, R&D | 4,764 0.0062% | $8.71 | $41,495 | -1.28% | ||
| 2024-02-01 | Sale | SVP, GC & CORPORATE SECRETARY | 4,764 0.0062% | $8.71 | $41,495 | -1.28% | ||
| 2024-02-01 | Sale | CHIEF FINANCIAL OFFICER | 3,818 0.0048% | $8.53 | $32,573 | -1.28% | ||
| 2024-02-01 | Sale | CHIEF MEDICAL OFFICER | 2,174 0.0028% | $8.53 | $18,547 | -1.28% | ||
| 2024-02-01 | Sale | SVP, CHIEF ACCOUNTING OFFICER | 2,820 0.0036% | $8.53 | $24,058 | -1.28% | ||
| 2024-01-23 | Sale | CHIEF EXECUTIVE OFFICER | 7,873 0.0101% | $8.96 | $70,542 | -7.32% |
Insider Historical Profitability
| Meckler Jeffrey A | director | 81000 0.0931% | $17.18 | 3 | 1 | +66.46% |
| Shkreli Martin | 1765168 2.0281% | $17.18 | 39 | 8 | +21.5% | |
| ASELAGE STEVE | 146919 0.1688% | $17.18 | 4 | 37 | +123.45% | |
| Richardson Steven Gary | director | 129165 0.1484% | $17.18 | 3 | 0 | +123.82% |
| PANOFF MARC L | Chief Financial Officer | 121100 0.1391% | $17.18 | 1 | 0 | +138.48% |
Institutional Investor Ownership
| BlackRock | $60.11M | 10.24 | 7.8M | -1.53% | -$933,634.74 | <0.01 | |
| Armistice Capital Llc | $57.83M | 9.85 | 7.5M | +1.57% | +$894,360.00 | 0.19 | |
| Deep Track Capital Lp | $56.82M | 9.68 | 7.37M | 0% | +$0 | 0.26 | |
| State Street | $50.95M | 8.68 | 6.61M | +23.47% | +$9.69M | <0.01 | |
| The Vanguard Group | $48.31M | 8.23 | 6.27M | +13.61% | +$5.79M | <0.01 |